SK284143B6 - Kryštalická forma II 2-metyl-4-(4-metyl-1-piperazinyl)-10H- tieno[2,3-b][1,5]benzodiazepínu, spôsob jej prípravy a farmaceutický prostriedok, ktorý ju obsahuje - Google Patents

Kryštalická forma II 2-metyl-4-(4-metyl-1-piperazinyl)-10H- tieno[2,3-b][1,5]benzodiazepínu, spôsob jej prípravy a farmaceutický prostriedok, ktorý ju obsahuje Download PDF

Info

Publication number
SK284143B6
SK284143B6 SK1218-97A SK121897A SK284143B6 SK 284143 B6 SK284143 B6 SK 284143B6 SK 121897 A SK121897 A SK 121897A SK 284143 B6 SK284143 B6 SK 284143B6
Authority
SK
Slovakia
Prior art keywords
methyl
thieno
benzodiazepine
piperazinyl
crystalline form
Prior art date
Application number
SK1218-97A
Other languages
English (en)
Slovak (sk)
Other versions
SK121897A3 (en
Inventor
Charles Arthur Bunnell
Barry Arnold Hendriksen
Samuel D. Larsen
Original Assignee
Eli Lilly And Company
Lilly Industries Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23621056&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK284143(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Company, Lilly Industries Limited filed Critical Eli Lilly And Company
Publication of SK121897A3 publication Critical patent/SK121897A3/sk
Publication of SK284143B6 publication Critical patent/SK284143B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
SK1218-97A 1995-03-24 1996-03-22 Kryštalická forma II 2-metyl-4-(4-metyl-1-piperazinyl)-10H- tieno[2,3-b][1,5]benzodiazepínu, spôsob jej prípravy a farmaceutický prostriedok, ktorý ju obsahuje SK284143B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40956695A 1995-03-24 1995-03-24
PCT/US1996/003917 WO1996030375A1 (en) 1995-03-24 1996-03-22 Process and crystal forms of 2-methyl-thieno-benzodiazepine

Publications (2)

Publication Number Publication Date
SK121897A3 SK121897A3 (en) 1998-03-04
SK284143B6 true SK284143B6 (sk) 2004-10-05

Family

ID=23621056

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1218-97A SK284143B6 (sk) 1995-03-24 1996-03-22 Kryštalická forma II 2-metyl-4-(4-metyl-1-piperazinyl)-10H- tieno[2,3-b][1,5]benzodiazepínu, spôsob jej prípravy a farmaceutický prostriedok, ktorý ju obsahuje

Country Status (49)

Country Link
US (1) US5736541A (hu)
EP (3) EP0733635B1 (hu)
JP (1) JPH11502535A (hu)
KR (1) KR100399688B1 (hu)
CN (1) CN1065536C (hu)
AP (1) AP828A (hu)
AR (2) AR002719A1 (hu)
AT (4) ATE204280T1 (hu)
AU (1) AU706471B2 (hu)
BG (1) BG62619B1 (hu)
BR (1) BR9607790A (hu)
CA (1) CA2214005C (hu)
CH (1) CH690579A5 (hu)
CO (1) CO4650278A1 (hu)
CZ (1) CZ292688B6 (hu)
DE (4) DE19681286T1 (hu)
DK (4) DK0733635T3 (hu)
EA (1) EA000149B1 (hu)
EE (1) EE03489B1 (hu)
EG (1) EG23659A (hu)
ES (3) ES2208220T3 (hu)
FI (1) FI973750A (hu)
GB (1) GB2313835B (hu)
HK (1) HK1013988A1 (hu)
HU (1) HU224989B1 (hu)
IL (1) IL117610A (hu)
IS (1) IS1896B (hu)
LT (1) LT4349B (hu)
LU (1) LU90096B1 (hu)
LV (1) LV12018B (hu)
MY (1) MY114701A (hu)
NO (1) NO314663B1 (hu)
NZ (1) NZ306110A (hu)
OA (1) OA10510A (hu)
PA (1) PA8353701A1 (hu)
PE (1) PE44897A1 (hu)
PL (1) PL183723B1 (hu)
PT (3) PT733635E (hu)
RO (1) RO118872B1 (hu)
SE (1) SE9703205D0 (hu)
SI (4) SI1095941T1 (hu)
SK (1) SK284143B6 (hu)
SV (1) SV1996000031A (hu)
TR (1) TR199701017T1 (hu)
TW (2) TW513432B (hu)
UA (1) UA44765C2 (hu)
WO (1) WO1996030375A1 (hu)
YU (1) YU49478B (hu)
ZA (2) ZA962342B (hu)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
WO1997011700A1 (en) * 1995-09-29 1997-04-03 Eli Lilly And Company Method for treating a tic disorder
UA57727C2 (uk) * 1996-03-11 2003-07-15 Елі Ліллі Енд Компані Спосіб лікування надмірної агресивності
JP2001517202A (ja) * 1996-03-25 2001-10-02 イーライ・リリー・アンド・カンパニー 痛み処置方法
EA000976B1 (ru) * 1996-03-25 2000-08-28 Эли Лилли Энд Компани Композиция для снятия боли и способ снятия боли
WO1997035585A1 (en) * 1996-03-25 1997-10-02 Eli Lilly And Company Anesthetic method
CA2250186A1 (en) * 1996-03-25 1997-10-02 Eli Lilly And Company Method for treating migraine pain
HU226167B1 (hu) * 1996-09-23 2008-05-28 Lilly Co Eli Olanzapin-dihidrát D, elõállítása és az azt tartalmazó gyógyszerkészítmények
ZA978515B (en) * 1996-09-23 1999-03-23 Lilly Co Eli Intermediates and process for preparing olanzapine
ZA982917B (en) * 1997-04-15 1999-10-06 Lilly Co Eli Method for treating cerebral focal stroke.
US20030022889A1 (en) * 1997-04-15 2003-01-30 Bymaster Franklin P. Method for providing neuro-protective effects
AU6955998A (en) * 1997-04-15 1998-11-11 Eli Lilly And Company Method for providing neuro-protective effects
DK1155696T3 (da) * 1997-04-15 2004-07-12 Lilly Co Eli Anvendelse af olanzapin til fremstillingen af et medikament til neurobeskyttelse
USRE43932E1 (en) 1997-07-18 2013-01-15 Novartis Ag Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
US6617321B2 (en) * 1997-09-30 2003-09-09 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
BR9914156A (pt) * 1998-09-30 2001-06-26 Lilly Co Eli Formulação de 2-metil-tieno-benzodiazepina
FR2802101B1 (fr) 1999-12-10 2003-02-28 Aventis Pharma Sa Association de cymemazine et d'un neuroleptique atypique
US6348458B1 (en) 1999-12-28 2002-02-19 U & I Pharmaceuticals Ltd. Polymorphic forms of olanzapine
US7022698B2 (en) 1999-12-28 2006-04-04 U & I Pharmaceuticals, Ltd. Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof
EP1246827B1 (en) * 1999-12-28 2005-04-13 Cipla Limited New polymorphic forms of olanzapine
SK2502003A3 (en) * 2000-08-31 2004-03-02 Reddys Lab Ltd Dr Process for preparation of hydrates of olanzapine and their conversion into crystalline forms of olanzapine
WO2002019998A2 (en) * 2000-09-08 2002-03-14 Eli Lilly And Company A method of treating weight gain associated with atypical antipsychotic use
US6740753B2 (en) 2001-01-04 2004-05-25 Geneva Pharmaceuticals, Inc. Olanzapine crystal modification
CA2464306A1 (en) * 2001-10-29 2003-05-08 Dr. Reddy's Laboratories Ltd. Olanzapine dihydrate-ii a process for its preparation and use thereof
EP2108651A1 (en) 2001-12-24 2009-10-14 Sun Pharmaceuticals Industries Ltd. Crystalline form I of 2-methyl-4-(4-methyl-1-piperazinyl) 10H thieno[2,3-B][1,5] benzodiazepine
US20100311701A1 (en) * 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
WO2004089313A2 (en) * 2003-04-01 2004-10-21 Transform Pharmaceuticals, Inc. Novel olanzapine forms and related methods of treatment
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
WO2003074474A2 (en) * 2002-03-01 2003-09-12 University Of South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
EP2266590A3 (en) 2002-02-22 2011-04-20 Shire LLC Active agent delivery sytems and methods for protecting and administering active agents
PL196814B1 (pl) 2002-05-17 2008-02-29 Inst Farmaceutyczny Sposób wytwarzania odmiany polimorficznej I olanzapiny i jej solwaty
US7297789B2 (en) 2002-05-31 2007-11-20 Sandoz, Inc. Process of preparation of olanzapine form I
CA2489984A1 (en) * 2002-06-21 2003-12-31 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
SI21270A (sl) * 2002-07-15 2004-02-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Kristalne oblike olanzapina in postopki za njihovo pripravo
PL202856B1 (pl) * 2002-12-20 2009-07-31 Adamed Spo & Lstrok Ka Z Ogran Sposób otrzymywania farmaceutycznie czystej polimorficznej postaci I olanzapiny
AU2003300324A1 (en) * 2002-12-24 2004-07-22 Teva Pharmaceutical Industries Ltd. Novel crystal forms of olanzapine, methods for their preparation and method for the preparation of known olanzapine crystal forms
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
US20060135547A1 (en) * 2003-03-12 2006-06-22 Toth Zoltan G Stable pharmaceutical compositions of desloratadine and processes for preparation of polymorphic forms of desloratadine
ES2232332T3 (es) * 2003-03-12 2007-08-16 Teva Pharmaceutical Industries Ltd Composiciones farmaceuticas estables de desloratadina.
GB0314149D0 (en) * 2003-06-18 2003-07-23 Generics Uk Ltd Novel amorphous forms
GB0326148D0 (en) 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
WO2005049090A2 (en) * 2003-11-18 2005-06-02 3M Innovative Properties Company Olanzapine containing transdermal drug delivery compositions
CA2551806A1 (en) * 2003-12-22 2005-07-14 Teva Pharmaceutical Industries, Ltd. Methods of preparing olanzapine
US20050272720A1 (en) * 2004-01-27 2005-12-08 Rolf Keltjens Process for making olanzapine Form I
WO2005070938A1 (en) 2004-01-27 2005-08-04 Synthon B.V. Stable salts of olanzapine
ES2253091B1 (es) 2004-07-27 2007-02-01 Inke, S.A. Solvato mixto de olanzapina, procedimiento para su obtencion y procedimiento de obtencion de la forma i de olanzapina a partir del mismo.
US7829700B2 (en) 2004-09-06 2010-11-09 Shasun Chemicals And Drugs Limited Process for preparation of a pharmaceutically pure polymorphic form I of Olanzapine
EP2623095A1 (en) * 2004-11-16 2013-08-07 Elan Pharma International Limited Injectable nanoparticulate olanzapine formulations
SI1838716T1 (sl) 2005-01-05 2011-10-28 Lilly Co Eli Olanzapin pamoat dihidrat
CZ297214B6 (cs) * 2005-02-02 2006-10-11 Zentiva, A. S. Lécivý prípravek obsahující jako úcinnou slozku olanzapin a zpusob jeho výroby
EP1863775A4 (en) * 2005-03-21 2009-11-11 Reddys Lab Ltd Dr PROCESS FOR THE PREPARATION OF A CRYSTALLINE FORM I OF OLANZAPINE
US20070021605A1 (en) * 2005-07-20 2007-01-25 Rolf Keltjens Process and composition for making olanzapine form i
WO2007020080A1 (en) * 2005-08-17 2007-02-22 Synthon B.V. A process for making olanzapine form i
GB0522474D0 (en) 2005-11-03 2005-12-14 Actavis Group A pharmaceutical formulation
HUP0501046A2 (en) * 2005-11-11 2007-08-28 Egis Gyogyszergyar Nyilvanosan Process for the preparation of olanzapine
US8222184B2 (en) 2006-03-07 2012-07-17 Ncr Corporation UV and thermal guard
US8367580B2 (en) 2006-03-07 2013-02-05 Ncr Corporation Dual-sided thermal security features
US8721202B2 (en) 2005-12-08 2014-05-13 Ncr Corporation Two-sided thermal print switch
ES2279715B1 (es) 2005-12-26 2008-06-01 Laboratorios Lesvi, S.L. Formulacion oral de olanzapina.
US7834176B2 (en) 2006-01-26 2010-11-16 Sandoz Ag Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E
US20070293479A1 (en) * 2006-05-18 2007-12-20 Osinga Niels J Olanzapine pharmaceutical composition
AR063043A1 (es) * 2006-09-29 2008-12-23 Synthon Bv Composicion farmaceutica de olanzapina
US8039461B1 (en) 2006-11-10 2011-10-18 Pisgah Laboratories, Inc. Physical states of a pharmaceutical drug substance
US7718649B1 (en) 2006-11-10 2010-05-18 Pisgah Labs, Inc. Physical states of a pharmaceutical drug substance
PL381564A1 (pl) 2007-01-22 2008-08-04 Koźluk Tomasz Nobilus Ent Sposób wytwarzania zasadniczo czystej odmiany polimorficznej I olanzapiny
CA2591644A1 (en) * 2007-06-14 2008-12-14 Apotex Pharmachem Inc. Novel processes to form-i of olanzapine
US9056488B2 (en) 2007-07-12 2015-06-16 Ncr Corporation Two-side thermal printer
US8883863B1 (en) 2008-04-03 2014-11-11 Pisgah Laboratories, Inc. Safety of psuedoephedrine drug products
CN101735239B (zh) * 2008-11-06 2011-08-31 齐鲁制药有限公司 一种无水奥氮平晶型ii的制备方法
EP2292624A1 (en) 2009-07-20 2011-03-09 LEK Pharmaceuticals d.d. Process for the purification of olanzapine
HRP20240109T1 (hr) 2010-08-23 2024-03-29 Alkermes Pharma Ireland Limited Postupci za liječenje povećanja tjelesne težine induciranog antipsihoticima
CN102093386B (zh) * 2011-01-05 2016-06-01 浙江华海药业股份有限公司 一种制备奥兰扎平晶型ⅱ的方法
WO2012153347A2 (en) 2011-05-04 2012-11-15 Zentiva K.S. Oral pharmaceutical composition of olanzapine form 1
PT2888590T (pt) 2012-08-21 2020-09-11 Janssen Pharmaceutica Nv Anticorpos para olanzapina e utilização destes
TR201910347T4 (tr) * 2012-08-21 2019-07-22 Janssen Pharmaceutica Nv Olanzapin haptenlerine yönelik antikorlar ve bunların kullanımı.
CN104736565B (zh) 2012-08-21 2019-03-12 詹森药业有限公司 利培酮半抗原的抗体及其用途
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
CN103848847B (zh) * 2012-12-04 2018-02-06 广东东阳光药业有限公司 一种改进制备奥氮平及其晶型ii的方法
JP6008734B2 (ja) * 2012-12-20 2016-10-19 株式会社トクヤマ オランザピンｉｉ型結晶の製造方法
CN103145731B (zh) * 2013-02-26 2014-02-19 江苏豪森药业股份有限公司 奥氮平晶型及其制备方法和用途
WO2023139531A1 (en) 2022-01-20 2023-07-27 Teva Pharmaceuticals International Gmbh Olanzapine, compositions thereof and methods of use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4115568A (en) * 1974-11-26 1978-09-19 Lilly Industries Limited Thieno[3,2-b]-[1,5]benzodiazepines
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
CA1097233A (en) 1977-07-20 1981-03-10 George K. E. Gregory Packages
US4237279A (en) * 1979-07-27 1980-12-02 Eli Lilly And Company Crystalline 3-hydroxycephalosporin solvates
IE53696B1 (en) 1981-12-02 1989-01-18 Wyeth John & Brother Ltd Solid shaped articles
US5079018A (en) 1989-08-14 1992-01-07 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
US5039540A (en) 1989-08-14 1991-08-13 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
EP0582368B1 (en) * 1992-05-29 2001-01-24 Eli Lilly And Company Limited Thienobenzodiazepine derivatives for treatment of CNS disorders
US5439888A (en) * 1994-03-04 1995-08-08 Eli Lilly And Company Antithrombotic agents
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine

Also Published As

Publication number Publication date
CH690579A5 (de) 2000-10-31
GB2313835A (en) 1997-12-10
OA10510A (en) 2002-04-24
HUP9802824A3 (en) 2000-01-28
NZ306110A (en) 1998-09-24
AP828A (en) 2000-04-28
IL117610A (en) 2001-08-26
GB2313835B (en) 1998-09-16
UA44765C2 (uk) 2002-03-15
IS4564A (is) 1997-09-22
US5736541A (en) 1998-04-07
PA8353701A1 (es) 1998-09-18
PT1445259E (pt) 2006-10-31
EP1095941B1 (en) 2003-10-08
EP1095941A1 (en) 2001-05-02
DK0733635T3 (da) 2001-10-08
MY114701A (en) 2002-12-31
PL183723B1 (pl) 2002-07-31
DE19681286T1 (de) 1998-04-02
CN1065536C (zh) 2001-05-09
SI0733635T1 (en) 2002-06-30
CA2214005A1 (en) 1996-10-03
ES2159346T3 (es) 2001-10-01
ATA902196A (de) 2000-01-15
SV1996000031A (es) 1998-03-27
IS1896B (is) 2003-10-20
CZ292688B6 (cs) 2003-11-12
DE69636313T2 (de) 2007-05-31
SE9703205L (sv) 1997-09-05
DE69630324T2 (de) 2004-07-29
BG62619B1 (bg) 2000-03-31
GB9719819D0 (en) 1997-11-19
EA000149B1 (ru) 1998-10-29
EG23659A (en) 2007-03-26
AU706471B2 (en) 1999-06-17
BG101900A (en) 1999-03-31
HU224989B1 (en) 2006-05-29
DE69636313D1 (de) 2006-08-10
HK1013988A1 (en) 1999-09-17
CA2214005C (en) 2001-07-03
LV12018B (en) 1998-09-20
ES2266719T3 (es) 2007-03-01
LU90096B1 (fr) 1997-07-22
ZA962342B (en) 1997-09-22
TW513432B (en) 2002-12-11
FI973750A0 (fi) 1997-09-22
SE9703205D0 (sv) 1997-09-05
YU17796A (sh) 1999-03-04
NO314663B1 (no) 2003-04-28
DE69614426T2 (de) 2002-05-23
ATE251627T1 (de) 2003-10-15
ATE204280T1 (de) 2001-09-15
NO974365L (no) 1997-09-22
AR002719A1 (es) 1998-04-29
ZA962344B (en) 1997-09-22
BR9607790A (pt) 1998-07-07
SK121897A3 (en) 1998-03-04
CO4650278A1 (es) 1998-09-03
DE69614426D1 (de) 2001-09-20
EP1445259A1 (en) 2004-08-11
ATE331719T1 (de) 2006-07-15
HUP9802824A2 (hu) 1999-06-28
AU5427996A (en) 1996-10-16
KR19980703188A (ko) 1998-10-15
DE69630324D1 (de) 2003-11-13
TW442488B (en) 2001-06-23
JPH11502535A (ja) 1999-03-02
ES2208220T3 (es) 2004-06-16
AP9701065A0 (en) 1997-10-31
AR010448A1 (es) 2000-06-28
EP0733635A1 (en) 1996-09-25
PL322501A1 (en) 1998-02-02
CZ300097A3 (en) 1997-12-17
NO974365D0 (no) 1997-09-22
WO1996030375A1 (en) 1996-10-03
CN1179160A (zh) 1998-04-15
EA199700262A1 (ru) 1998-02-26
TR199701017T1 (xx) 1998-01-21
EE9700232A (et) 1998-04-15
FI973750A (fi) 1997-09-22
SI9620040A (sl) 1998-06-30
SI9620040B (sl) 2002-02-28
EE03489B1 (et) 2001-08-15
EP1445259B1 (en) 2006-06-28
PE44897A1 (es) 1997-10-22
MX9707183A (es) 1997-11-29
RO118872B1 (ro) 2003-12-30
LV12018A (lv) 1998-04-20
YU49478B (sh) 2006-05-25
DK1095941T3 (da) 2004-02-16
KR100399688B1 (ko) 2004-02-18
SI1095941T1 (en) 2003-12-31
PT1095941E (pt) 2004-02-27
LT97148A (en) 1998-01-26
DK1445259T3 (da) 2006-10-16
LT4349B (lt) 1998-05-25
PT733635E (pt) 2001-12-28
DK108997A (da) 1997-11-12
EP0733635B1 (en) 2001-08-16
SI1445259T1 (sl) 2006-10-31
IL117610A0 (en) 1996-07-23
AT406771B (de) 2000-08-25

Similar Documents

Publication Publication Date Title
SK284143B6 (sk) Kryštalická forma II 2-metyl-4-(4-metyl-1-piperazinyl)-10H- tieno[2,3-b][1,5]benzodiazepínu, spôsob jej prípravy a farmaceutický prostriedok, ktorý ju obsahuje
SK128297A3 (en) Oral 2-methyl-thieno-benzodiazepine formulation and method of preparing the same
PL196068B1 (pl) Związek będący krystalicznym polimorfem, Dihydratem E olanzapiny i sposób wytwarzania zasadniczo czystej postaci II olanzapiny
KR19990087715A (ko) 자폐증의 치료 방법
WO1996038151A1 (en) Method for treating cognitive dysfunction
MXPA97007183A (en) A process and glass forms of 2-methyl-tieno-benzodiazep
IL126157A (en) Medicinal products containing olenzapine for the treatment of hyper-aggression
US20020177590A1 (en) Method for treating cognitive dysfunction
JPS61112074A (ja) エルゴリン誘導体及び該誘導体を含む医薬品
MXPA98007430A (en) Medications for the treatment of the car

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20140322